Montrouge, France, September 5, 2023
DBV Technologies to Participate in Upcoming Investor Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11(th) ?13(th) in New York, NY. Daniel Tassé, Chief Executive Officer, will represent the company in a fireside chat session on Tuesday, September 12(th) at 4:00 pm EST, as well as one-on-one investor meetings throughout the day.
A live webcast of the presentation will be available on the Investors & Media section of the Company's website: https://journey.ct.events/view/4f45c9c0-d6f0- 4fe2-a5b2-ffc6be420349.
A replay will also be available on DBV Technologies' website for 90 days after the event.
About DBV Technologies
DBV Technologies is developing Viaskin(TM), an investigational proprietary
technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT(TM), and is DBV Technologies'
method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company
is dedicated to safely transforming the care of food allergic patients. DBV Technologies' food allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge, France, and North
American operations in Basking Ridge, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and
the Company's ADSs (each representing one-half of one ordinary share) are traded
on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact
Katie Matthews
DBV Technologies
+1 857-529-2563
katie.matthews@dbv-technologies.com (mailto:katie.matthews@dbv- technologies.com)
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com (mailto:angela.marcucci@dbv- technologies.com)
Viaskin and EPIT are trademarks of DBV Technologies.
Â